Analyst firms · Morgan Stanley · BPMC

Morgan Stanley BPMC price target and rating history

Blueprint Medicines Corporation (BPMC) · Health Care

Morgan Stanley rates Blueprint Medicines Corporation (BPMC) Equal-Weight with a $100 price target, as of its latest action on Mar 20, 2025. It has published 5 rating actions on BPMC since July 2021, including 0 upgrades and 0 downgrades.

Current rating
Equal-Weight
Price target
$100
Median target, all firms
Too few
Actions on BPMC
5

Morgan Stanley price target on BPMC

$111$102$9220222023202420252026
Morgan Stanley price target on BPMC, each point a stated target, July 2021 to March 2025.

Every Morgan Stanley rating on BPMC

Questions about Morgan Stanley and BPMC

What is Morgan Stanley's price target for BPMC?
Morgan Stanley's latest stated price target for Blueprint Medicines Corporation (BPMC) is $100, from its action on Mar 20, 2025.
What is Morgan Stanley's rating on BPMC?
Morgan Stanley rates BPMC Equal-Weight, a neutral rating, as of Mar 20, 2025.
When did Morgan Stanley last change its view on BPMC?
On Mar 20, 2025, Morgan Stanley resumes coverage at Equal-Weight, price target $100.

More BPMC rating histories

All Morgan Stanley ratingsBPMC news and filingsEvery analyst firm

From rating actions in the Quantisnow feed. A target holds until the firm states a new one; a reiteration with no target keeps the last one. Not investment advice.